Navigation Links
Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
Date:10/12/2011

EAST BRUNSWICK, N.J., Oct. 12, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the company will release financial results for the third quarter 2011 prior to the open of the market on Thursday, November 3, 2011.

John H. Johnson, Chief Executive Officer and President, and Kenneth J. Zuerblis, Executive Vice President and Chief Financial Officer, will host an investment community conference call beginning at 9:00 a.m. Eastern Time on November 3, 2011 to discuss these results and to answer questions.

To participate by telephone, please dial 866-393-9370 (Domestic) or 706-679-1207 (International). The conference ID number is 17722127. The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on November 3, 2011 through 12:00 a.m. Eastern Time on November 17, 2011 by dialing 855-859-2056 (Domestic), alternate number 800-585-8367 or 404-537-3406 (International) and entering conference ID number 17722127.

About Savient Pharmaceuticals, Inc.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA.  MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT-IContact:Mary ColemanCarney NoensieSavient Pharmaceuticals, Inc.Burns McClellan(732) 418-9300(212) 213-0006information@savient.comcnoensie@burnsmc.com
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 15, 2017   Mostyn Law and Gulf Coast Regional ... Texas . The Mostyn Law family has had ... That is why Mostyn Law is partnering with Gulf ... show its appreciation. Blood supplies are running low. Gulf ... of hospital needs in August. That is why the blood center ...
(Date:8/14/2017)... Israel , Aug. 15, 2017  BrainStorm ... adult stem cell technologies for neurodegenerative diseases, announced financial ... "We are in ... 3 trial to investigate NurOwn ® in ALS," ... Officer of BrainStorm. "We have agreements with Mass. General ...
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... This week the The Voss Law Firm celebrates ... Bill Voss, the firm grew quickly and has built a reputation for excellence, trust, ... get the money they deserve from their insurance companies. , The Voss Law ...
(Date:8/23/2017)... DC (PRWEB) , ... August 23, 2017 , ... ... Oxygen Therapy continues to prove the safety and efficacy of HBOT in treating ... clinics across the US, points to research showing the similarities of the wounds ...
(Date:8/23/2017)... ... August 23, 2017 , ... PreCheck, Inc., ... 2017 Inc. 5000 with a three-year sales growth of 49 percent . ... and comprises the most comprehensive look at America’s independent entrepreneurs. This represents PreCheck’s ...
(Date:8/23/2017)... ... 2017 , ... MobilityWorks ®, the nation's largest retailer ... Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. MobilityWorks (aka WMK) ... the twelfth year that the company has been included on the list. , ...
(Date:8/23/2017)... ... August 23, 2017 , ... A new literature review ... , points out that therapeutic modalities (physical therapy) is an important part of ... report, a wider scope of physical therapy options is showing promising results and ...
Breaking Medicine News(10 mins):